Company intelligence / Profile preview

SGS

Geneva, Geneva, Switzerlandsgs.com ↗

Ownership: Public · SGSN
Employees: ~99600
Development stage: Commercial

Overview

SGS does not develop its own therapeutics but provides comprehensive analytical testing, biosafety assessment, regulatory support, and quality control services to pharmaceutical and biopharmaceutical companies at every stage of the product lifecycle. Recent expansions have enhanced their biologics testing capabilities in North America to meet growing demand for large molecule drug development support. No clinical results are applicable as they do not sponsor their own clinical programs.

Therapeutic areas: Other
Modalities: Small moleculesBiologics (proteins, peptides, monoclonal antibodies)Antibody-drug conjugatesCell therapiesGene therapiesMedical devices
Industry: Contract Research Organization

Partnerships

Not specifically listed

Financials

Market cap: $24.5B
Total revenue: $8.5B
Enterprise value: $29.3B

Beyond the preview

Go deeper on SGS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGS.